Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q02742

UPID:
GCNT1_HUMAN

ALTERNATIVE NAMES:
Core 2 beta-1,6-N-acetylglucosaminyltransferase; Core 2-branching enzyme; Core2-GlcNAc-transferase; Leukocyte type core 2 beta-1,6-N-acetylglucosaminyltransferase

ALTERNATIVE UPACC:
Q02742; Q6DJZ4

BACKGROUND:
The enzyme Core 2-branching enzyme, known for its glycosyltransferase activity, is instrumental in the formation of branched mucin-type core 2 O-glycans from UDP-GlcNAc onto mucin-type core 1 O-glycan. Its function extends to the synthesis of stage-specific embryonic antigen 1 (SSEA-1) determinant by transferring GlcNAc moiety to GalGb4Cer globosides. This process is crucial for the display of selectin ligand sialyl Lewis X epitope by myeloid cells, impacting their recruitment and homeostasis at inflammatory sites.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Core 2-branching enzyme could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.